Introduction and Context
Alcohol use disorder (AUD) and alcohol‑associated liver disease (ALD) are rising in prevalence and driving increasing morbidity, mortality, and healthcare costs worldwide. In September 2025, the National Institute on Alcohol Abuse and Alcoholism (NIAAA) convened a multistakeholder workshop to define practical, scalable strategies to reduce the ALD burden in the general population. The consensus—summarized in Asrani et al., Lancet Gastroenterology & Hepatology (2025)—frames a multipronged approach spanning population measures, routine screening, non‑invasive liver fibrosis assessment, clinical care pathways, and system redesign to integrate addiction and liver care.
This article summarizes the workshop consensus and related authoritative evidence, highlights core recommendations by topic, contrasts key changes or emphases compared with prior guidance, and translates recommendations into clinical and public‑health practice.
New Guideline Highlights
Major themes and takeaways from the 2025 workshop consensus:
– Prioritize upstream screening for unhealthy alcohol use in primary care and general medical settings using brief validated tools (AUDIT‑C). Thresholds advocated: AUDIT‑C ≥3 for women and ≥4 for men trigger further assessment.
– Triage patients with elevated consumption scores to non‑invasive fibrosis assessment using blood‑based tests (eg, Fibrosis‑4 [FIB‑4]) as the first step, followed by imaging‑based tests (eg, transient elastography) when indicated. Sequential testing improves positive predictive value and referral efficiency.
– Expand and standardize care pathways: implement screening, brief intervention, and referral to treatment (SBIRT) for non‑dependent unhealthy drinkers; provide evidence‑based pharmacotherapy and behavioral interventions for AUD; and create multidisciplinary ALD clinics that co‑manage liver disease, addiction, and mental health.
– Embed integrated care models and patient navigation (substance‑use navigators) to improve engagement, adherence, and outcomes.
– Promote population‑level policies (pricing, availability controls, advertising limits) alongside clinical measures to reduce aggregate alcohol consumption.
Key takeaway for clinicians: routinely screen adults for unhealthy alcohol use, use validated tools, escalate to non‑invasive fibrosis testing when screening is positive, and ensure clear pathways for AUD treatment and liver care — ideally within integrated teams.
Updated Recommendations and Key Changes
How the workshop consensus extends or clarifies prior guidance:
– Screening expansion: The workshop emphasizes systematic, population‑level screening with AUDIT‑C thresholds that are widely validated (≥3 women; ≥4 men). This aligns with prior USPSTF recommendations favoring universal screening in adults, but the Lancet consensus stresses implementation in more clinical contexts and routine use in electronic health records to capture population exposure.
– Sequential non‑invasive testing (NIT): Earlier guidance often recommended blood‑based indices or elastography alone. The 2025 consensus advocates sequential testing—start with an inexpensive blood index (eg, FIB‑4), then confirm with imaging elastography if FIB‑4 is indeterminate or elevated—to optimize resource use and referral specificity.
– Integrated delivery models: While prior hepatology guidance endorsed referral for specialized care, the workshop advances specific models—multidisciplinary ALD clinics, co‑located addiction and hepatology services, and substance‑use navigators—to reduce fragmentation and improve outcomes.
– Population measures re‑emphasized: The workshop reasserts that clinical measures alone are insufficient and highlights policy levers (taxation, minimum unit pricing, reduced availability, advertising controls) as essential complements.
Evidence driving updates: rising ALD incidence and mortality, better validation of non‑invasive tests in general populations, accumulating trials demonstrating SBIRT effectiveness for non‑dependent unhealthy drinking, and implementation research on integrated care improving engagement.
Topic‑by‑Topic Recommendations
Note: The workshop produced consensus recommendations rather than a formal GRADE table. Where possible, recommendations are linked to existing evidence and prior guideline statements.
Screening for unhealthy alcohol use
– Who: All adults in primary care and general medical settings.
– How: Use a validated brief screen—AUDIT‑C (3 questions) is recommended for efficiency and accuracy. (Reference: AUDIT and AUDIT‑C guidance.)
– Thresholds prompting further evaluation: AUDIT‑C ≥3 (women) and ≥4 (men).
– Frequency: Annually for most adults; at each relevant visit for higher‑risk groups (eg, patients with abnormal liver tests, mental health disorders, or known AUD history).
– Rationale: Early detection enables SBIRT for non‑dependent unhealthy drinkers and directs higher‑risk patients into fibrosis assessment pathways.
Assessment of liver disease risk (non‑invasive tests)
– First‑line test after positive alcohol screen: Blood‑based fibrosis indices, primarily FIB‑4, because of low cost and broad availability.
– Typical cutpoints used in practice: FIB‑4 2.67 (high risk). For older adults, clinicians should use age‑adjusted cutoffs because FIB‑4 increases with age.
– Second‑line: Imaging‑based elastography (eg, transient elastography/VCTE) for indeterminate or elevated FIB‑4 to improve positive predictive value and guide referral decisions.
– Elastography thresholds vary by device and etiology; many centers use ~8 kPa to suggest clinically significant fibrosis and higher thresholds (eg, >12–14 kPa) for cirrhosis. Local laboratory/clinic-specific cutoffs should be harmonized and documented.
– Sequential approach: FIB‑4 → VCTE if FIB‑4 elevated/indeterminate → referral to hepatology if elastography indicates advanced fibrosis/cirrhosis or if clinical concern persists.
– Rationale: Sequential testing reduces unnecessary specialty referrals, improves detection of clinically important fibrosis, and is feasible in primary care settings.
Brief intervention, AUD treatment, and linkage to specialty care
– SBIRT: Screening, Brief Intervention, and Referral to Treatment remains effective for adults with unhealthy alcohol use who are not alcohol dependent (USPSTF grade B evidence). Brief counseling should be delivered in primary care and community settings.
– Pharmacotherapy for AUD: Offer evidence‑based medications where appropriate; in patients with liver disease choose agents with consideration of hepatic metabolism and safety.
– Naltrexone: effective for reducing heavy drinking but use caution in acute hepatic injury; monitor liver enzymes.
– Acamprosate: primarily renally excreted and often preferred in patients with advanced liver disease when renal function allows.
– Baclofen: has shown benefit in some trials for promoting abstinence in patients with liver disease (considered in selected patients); dosing and monitoring required.
– Disulfiram: limited by adherence and safety concerns; consider only in selected, closely supervised cases.
– Psychosocial interventions: Cognitive behavioral therapy, motivational interviewing, mutual‑help groups (eg, Alcoholics Anonymous), and contingency management are integral.
– Referral criteria to hepatology: Evidence of advanced fibrosis/cirrhosis by NITs or clinical signs (eg, thrombocytopenia, portal hypertension), hepatic synthetic dysfunction, or significant transaminase elevations.
Multidisciplinary ALD clinics and integrated care
– Core elements: Co‑located hepatology, addiction psychiatry, social work/case management, mental health services, and care navigation.
– New roles: Substance‑use navigators and community health workers to help patients access pharmacotherapy, counseling, social supports, and, when indicated, transplant evaluation.
– Outcome goals: Increase engagement in AUD treatment, maintain abstinence or reduce consumption, detect and manage complications of liver disease early, and improve transplant candidacy and post‑transplant outcomes.
Special populations
– Pregnant people: Any alcohol use is discouraged; screen with AUDIT‑C or single‑question screens and provide counseling. Deferral of some pharmacotherapies for AUD is appropriate; coordinate specialty care.
– Adolescents and young adults: Use age‑appropriate screening and brief counseling; involve family and behavioral health as needed.
– Older adults: Use age‑adjusted cutoffs for fibrosis scores; consider polypharmacy and comorbidities when selecting AUD treatments.
Follow‑up and monitoring
– Low‑risk patients (normal FIB‑4, low consumption): brief counseling, periodic reassessment (annual or sooner if signs/symptoms change).
– Indeterminate or elevated NITs: expedited VCTE (or other imaging), repeat NITs at intervals if not referred; hepatology referral for confirmed advanced fibrosis or cirrhosis.
– Patients in treatment for AUD: monitor liver tests, adherence, psychiatric comorbidity, and social determinants (housing, employment) that affect outcomes.
Expert Commentary and Insights
Workshop panelists, including hepatologists, addiction specialists, primary care physicians, public‑health experts, and patient advocates, emphasized several points:
– “We must move screening upstream.” Routine screening in primary care and emergency departments will detect high‑risk drinking earlier and prevent progression to advanced liver disease.
– “Sequential non‑invasive testing is pragmatic.” Blood‑based indices like FIB‑4 are inexpensive and scalable; adding elastography for indeterminate results avoids overreferral while preserving sensitivity for clinically important fibrosis.
– “Integration beats referral.” Fragmented referrals drive drop‑off. Co‑location and integrated teams increase initiation and retention in AUD care and enable rapid liver disease management.
– “Policy matters.” Clinical care and screening cannot substitute for population‑level measures shown to reduce overall alcohol consumption (eg, taxation, reduced availability, marketing controls).
Areas of controversy and research priorities highlighted by experts:
– Best thresholds and algorithms for FIB‑4 and elastography in age groups and different ethnic populations—standardization is needed.
– Comparative effectiveness of pharmacotherapies for AUD specifically in patients with advanced liver disease; safety data remain limited for some agents in decompensated cirrhosis.
– Implementation strategies: how to embed screening and NITs in workflows without overwhelming primary care, and how to finance multidisciplinary ALD clinics.
Practical Implications for Clinicians and Health Systems
Actionable steps for clinics and health systems:
1. Implement routine AUDIT‑C screening in electronic health record workflows, with automated prompts and documentation fields.
2. Establish a defined NIT pathway: FIB‑4 calculation automated from routine labs (age, AST, ALT, platelets) → reflex VCTE ordering for indeterminate or elevated results → clear referral thresholds to hepatology.
3. Train primary care clinicians in SBIRT and create rapid referral links to addiction services and behavioral health.
4. Pilot multidisciplinary ALD clinics or virtual co‑management programs to bridge hepatology and addiction care for high‑risk patients.
5. Measure success with population and clinical metrics: per‑capita alcohol consumption, rates of advanced fibrosis detection, AUD treatment initiation and retention, ALD‑related hospitalizations, mortality, and healthcare costs.
Implementation challenges and solutions:
– Barrier: Limited access to elastography in resource‑constrained settings. Solution: Use age‑adjusted FIB‑4 and risk‑stratify referrals; consider mobile elastography programs or telehealth alliances.
– Barrier: Workforce shortages in addiction medicine. Solution: Expand training, use remote counseling, and integrate peer navigators and community health workers.
– Barrier: Payment models not aligned for multidisciplinary care. Solution: Advocate for bundled payments, value‑based incentives, and reimbursement for care navigation and integrated services.
Patient Vignette
David, a 48‑year‑old retail manager, attends a routine primary‑care visit. AUDIT‑C administered in the clinic is 5 (men threshold ≥4). A brief intervention is delivered immediately; David accepts blood testing and a FIB‑4 is automatically calculated from labs (FIB‑4 = 1.8, indeterminate). The clinic orders a transient elastography; VCTE returns 9.5 kPa, suggesting significant fibrosis. The clinic’s care navigator schedules a combined hepatology‑addiction intake: hepatology confirms advanced fibrosis, addiction psychiatry starts motivational interviewing and discusses pharmacotherapy options. Because David has preserved liver synthetic function, acamprosate is started and he enrolls in outpatient counseling. Over 12 months David reduces alcohol intake to abstinence, FIB‑4 and VCTE stabilize, and he remains engaged in the multidisciplinary clinic. This vignette illustrates the sequential screening and integrated care pathway advocated by the workshop.
Measuring Success and Policy Levers
Workshop‑endorsed success metrics:
– Clinical: decline in ALD‑related hospitalizations, earlier stage at detection, increased uptake of AUD treatment, and reduced mortality.
– Population: lower per‑capita alcohol consumption and prevalence of heavy episodic drinking.
– Economic: reduced health‑care costs related to end‑stage liver disease and transplant.
Policy-level actions to complement clinical strategies:
– Implement evidence‑based alcohol policies (eg, taxation, minimum unit pricing, restricting hours of sale) — WHO’s SAFER package outlines high‑impact interventions.
– Fund screening and integrated care infrastructure, including elastography access and care navigation.
– Support workforce development in addiction medicine and behavioral health integration.
References
– Asrani SK, Mellinger J, Sterling S, et al. Reducing alcohol‑associated liver disease burden in the general population. Lancet Gastroenterol Hepatol. 2025 Sep 18;10(12):1117–1131. doi:10.1016/S2468-1253(25)00193-1.
– World Health Organization. SAFER: A global package of interventions to reduce alcohol‑related harm. WHO; 2018. (https://www.who.int/publications/i/item/9789241515480)
– Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT‑C): an effective brief screening test for problem drinking. Arch Intern Med. 1998 Sep 14;158(16):1789–95.
– Babor TF, Higgins‑Biddle JC, Saunders JB, Monteiro MG. AUDIT: The Alcohol Use Disorders Identification Test. Guidelines for use in primary care. World Health Organization; 2001.
– Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317‑1325.
– US Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: recommendation statement. Ann Intern Med. 2013;159(3):210–218.
– European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: Management of alcohol‑related liver disease. J Hepatol. 2018.
– Addolorato G, et al. Baclofen efficacy in maintaining alcohol abstinence in alcohol‑dependent patients with cirrhosis: randomized controlled trial. (Selected trials reviewed in workshop materials and practice reviews.)
– National Institute on Alcohol Abuse and Alcoholism (NIAAA). Clinician’s Core Resource and brief interventions. (https://www.niaaa.nih.gov)
Conclusion
The 2025 NIAAA‑led workshop consensus summarized in Lancet Gastroenterology & Hepatology articulates a practical, evidence‑informed roadmap to reduce ALD burden: scale up routine screening with AUDIT‑C, adopt sequential non‑invasive fibrosis testing to triage referral, embed SBIRT and evidence‑based AUD treatments in clinical practice, and reconfigure health systems toward integrated multidisciplinary care. These clinical measures must be coupled with population policies that reduce alcohol availability and consumption. Implementation will require leadership, funding, and measurement; but the potential gains—fewer deaths, less severe liver disease at presentation, and lower societal costs—are substantial.